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Long-term effects of a new ketoacid—amino acid supplement in patients
with chronic renal failure. Nine patients with severe chronic renal
failure (mean glomerular filtration rate 4.8 mI/mm; mean serum creati-
nine 11.3 mg/dl) who were previously on a protein-restricted diet were
treated with a diet containing an average of 33 kcal/kg and 22.5 g/day of
mixed quality protein, supplemented by a combination of amino acids
and mixed salts formed between basic amino acids and keto-analogues
of essential amino acids. The supplement was designed to minimize or
reverse the amino acid abnormalities of chronic renal failure rather than
to meet the normal requirements for the essential amino acids; it
contained tyrosine, ornithine, and a high proportion of branched-chain
ketoacids, but no phenylalanine or tryptophan and very little methio-
nine. Within one month, serum urea nitrogen fell and serum albumin
and transferrin rose significantly; serum creatinine fell slightly. Hyper-
phosphatemia (present in three patients) was corrected. Nitrogen
balance, measured in seven of the nine patients, on the average was
neutral, as it was in a preceding control period on a 40 to 50 g/day
protein diet. Plasma tyrosine and threonine, which were subnormal
before therapy, rose to normal or high normal levels. Branched-chain
amino acids did not change. During a total of 63 patient-months of
therapy, no side effects or toxicity were observed, and serum albumin
and transferi-in did not change further. It is concluded that this specially
designed supplement added to a 20 to 25 g/d protein diet is an acceptable
regimen which can improve or maintain protein nutrition in patients
with severe chronic renal failure who would otherwise require dialysis.
Effet a long terme d'un nouveau mélange de cétoacides — d'amino acides
chez des malades ayant une insufilsance rénale chronique. Neuf malades
ayant une insuffisance rénale chronique sévère (filtration glomérulaire
moyenne 4,8 mI/mn, créatininémie moyenne 11,3 mg/dl) recevant
prealablement un régime pauvre en protéines, ont été traités avec an
régime apportant en moyenne 33 kcal/kg et 22,5 g/j de protéines mixtes,
auquel a été ajouté un mélange d'acides aminés et de sels d'acides
aminés basiques et de céto-analogues d'acides aminés essentiels. Ce
supplement a été concu plus pour diminuer ou supprimer les anomalies
des acides aminés au cours de l'insuffisance rénale chronique que pour
fournir les besoins normaux en acides aminés essentiels; il contenait de
Ia tyrosine, de l'ornithine et une grande proportion de cétoacides a
chaines ramifiées, mais ni phénylalanine, ni tryptophane, et trés peu de
méthionine. En moms d'un mois, l'azote uréique plasmatique a baissé;
Ia serum albumine et Ia transférine se soot élevées significativement, Ia
crCatininémie a legerement diminué. L'hyperphosphatémie (presente
chez trojs malades) a été corrigée. La balance azotée, mesurée chez
sept des neuf malades était nulle en moyenne, comme elle l'était au
cours de Ia période contrôle précédente, avec un régime comportant 40
a 50 glj de protéines. La tyrosine et Ia thrConine plasmatiques, infer-
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ieures ala normale avant traitement, se sont normalisées, ou ont atteint
des valeurs a la limite supérieure de Ia normale. Il n'y a pas eu de
modification des concentrations d'acides aminés a chaines ramifiées.
Pendant un traitement durant au total 63 mois-malade, il n'a pas été
observe d'effet secondaire ni de toxicité, et ii n'y a pas eu d'autre
modification de l'albumine ou de Ia transferrine plasmatique. Ii est
conclu que ce mélange spécialement concu, rajoutC a un régime
apportant 20 a 25 glj de protéines constitue un régime acceptable,
permettant d'amCliorer ou de maintenir l'apport protidique chez des
malades ayant une insuffisance rénale chronique sévère qui, autrement,
nécessiteraient Ia dialyse.
The dietary requirements for amino acids of patients with
chronic renal failure (CRF) are unknown but are likely to differ
from those of normal subjects, for two reasons. First, multiple
abnormalities of amino acid concentrations in plasma and
intracellular water of muscle are seen in uremia [11. Second,
several specific defects in amino acid metabolism have been
identified in renal failure, including impaired conversion of
citrulline to arginine [4], impaired hydroxylation of phenylala-
nine [5—9], accelerated destruction of valine [101, and altered
protein-binding of tryptophan [111.
Attempting to achieve normal plasma or intracellular concen-
trations of amino acids is one method ofjudging the adequacy of
dietary amino acid supplements; assessing protein nutrition is
another method. For uremic subjects, it is especially important
to ensure that the total intake of amino acids is sufficient to
maintain nitrogen equilibrium, but not excessive, which would
lead to unnecessary accumulation of waste nitrogen. One
means of achieving this goal is to supply a portion of daily
essential amino acid requirements as nitrogen-free amino acid
analogues [12, 131.
Several studies have documented the efficacy of supplements
containing nitrogen-free analogues of the branched-chain amino
acids, phenylalanine and methionine, plus the remaining essen-
tial amino acids, when added to a diet adequate in calories and
containing 20 to 25 g of protein unrestricted as to quality [13].
The acceptability of this diet appears to be greater than that of a
40 g protein diet containing predominantly high quality protein
[14].
The analogue supplements used in these studies usually
contained a relatively high proportion of the branched-chain
ketoacids, because these compounds are known to be decar-
boxylated oxidatively to some extent in the liver [151. In other
respects, the proportions of the individual components have
been based on requirements for normal subjects. Moreover, the
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I F 60 GN 2.9 106 15.5 17
2 F 43 Pc 3.5 105 11.6 7
3 M 78 GN 4.0 98 10.6 4
4 F 55 GN 5.1 96 11.0 13
5 M 51 DN 3.3 114 14.0 4
6 M 74 HN 5.2 126 9.5 4
7 M 48 HN 6.1 91 10.2 7
8 M 72 DN 7.0 79 6.8 3
9 M 49 HN 6.5 82 10.5 4
Mean 4.8 100 11.3 7.0
SEM —
a Abbreviations: GN, glomerulonephritis; PC, polycystic kidney disease; DN, diabetic nephropathy; HN, arteriolar nephrosclerosis; and N,
nitrogen.
b Glomerular filtration rate was estimated as the average of 24-hr creatinine and urea clearances.
Dose
Compound mmoles/day mg N/day
analogues have been provided as calcium salts, which probably
account for the occasional occurrence of hypercalcemia report-
ed in some studies [16—181, though not in all [13], and perhaps
for occasional gastrointestinal distress occurring at the start of
therapy [1].
Recently, we described the characteristics of mixed salts
formed between basic amino acids and branched-chain ketoac-
ids and preliminary results of the use of these salts in an
analogue supplement [19]. Based on those data, we have
designed an analogue supplement that includes these salts, a
small amount of methionine (as its hydroxy analogue), and
tyrosine but devoid of phenylalanine or tryptophan in any form.
This supplement was given to patients with CRF, and its
effectiveness was tested during long-term administration.
Methods
Three women and six men with severe chronic renal failure
were studied after obtaining informed consent. Characteristics
of these patients and duration of treatment are shown in Table
1. The composition of the mixture of amino acids and nitrogen-
free analogues is shown in Table 2. The doses of the keto-
analogues of the branched-chain amino acids are increased
above "normal" requirements for the respective amino acids,
and the mixture contains tyrosine, but no tryptophan or phenyl-
alanine; only a small quantity of the hydroxy-analogue of
methionine is included as the calcium salt. The chemical
characteristics of the mixed salts used are described elsewhere
[19].
Nitrogen balance was determined in six patients during two
consecutive 5-day periods; first, they consumed a diet with an
amount of protein similar to that they had been eating as
outpatients (determined by dietary recall); subsequently, their
protein intake was lowered to 20 to 25 g/day (average 22.5
g/day), and they were given the analogue supplement. The
effects of the control diet were always studied first because
there are beneficial effects of a-ketoisocaproate on nitrogen
balance that can be detected for as long as 7 days after
discontinuing the analogue supplement [201. Nitrogen balance
in a seventh patient was determined only while he received the
supplement. The other two patients declined to be admitted to
the hospital for balance studies. Caloric content of the diets was
33 3 kcal/kg/day and did not differ significantly between the
two balance periods. The patients took 1 mg folic acid and a B
vitamin complex tablet daily, and most patients also received
supplements of calcium.
Nitrogen balance studies were conducted as previously re-
ported [211. Balance was calculated as the difference between
nitrogen intake (IN) and the sum of urinary urea nitrogen
(UUN), urinary nonurea nitrogen (UNUN), fecal nitrogen (FN)
and the change in the body pool of urea nitrogen (z). Changes in
this pool were calculated from the '4C urea space, daily
measurements of body weight, and daily measurements of
serum urea nitrogen concentrations. No correction was made
for unmeasured losses of nitrogen. Statistical methods have
been reported previously [21].
Before starting the supplement and at 2- to 4-week intervals
thereafter, plasma was obtained after an overnight fast and
amino acid concentrations were measured by automated ion-
exchange chromatography. A total of 16 samples was obtained
before treatment, 18 samples during the first month, 13 during
the second, and 15 during the third and fourth months. For each
Patient
Age
Sex years
Table 1. Initial characteristics of patients and duration of therapy
Diagnosisa
Glomerular
filtration rateb
mI/mm
Serum values
Urea N Creatinine
mg/dl
Months of
treatment
Table 2. Composition of mixture "EE"
L-tyrosine
L-threonine
L-ornithine s-ketoisovalerate
L-ornithine a-ketoisocaproate
L.ornithine R,S-a-keto-3-methylvalerate
L-lysine a-ketoisovalerate
L-lysine a-ketoisocaproate
L-lysine R,S-u-keto-3-methylvalerate
L-histidine a-ketoisocaproate
Calcium D, L-c-hydroxy--y-methiolbutyrate
20 280
15 210
7 196
7 196
7 196
7 196
7 196
7 196
4 112
2 0
Total 83 1778
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Table 3. Effects of therapy on serum chemical values, means SEM
Initial
100.0 5.0
11.3 0.9
394- 0.1
209.0 + 22.0
9.0 + 0.3
4.9 0.6
4 to 6 weeks
87.0 6.0
10.1 - 0.8
4.1 4- 0.1
267.0 + 21.0
9.4 ÷ 0.2
3.9 0.2
Change
—12.0 2.0
—1.16 0.45
+0.27 0.06
+21.0 7.0
+0.4 0.3
1.0 0.6
pa
<0.01
<0.05
<0.01
<0.02
NS
NS
patient, a mean value at each of these time intervals was
calculated. The significance of these changes was evaluated by
Student's paired t test. Tryptophan could not be reliably
measured in these samples.
Serum chemical values were determined before treatment
and once or twice a month during treatment. The statistical
significance of changes was evaluated at 4 to 6 weeks and then
monthly by Student's paired t test.
The rate of progression of renal insufficiency was calculated
in seven patients by determining the linear regression slope of
the reciprocal of serum creatinine concentration against time
and the SEM of this slope [22]. In the other two patients,
insufficient data before therapy were available to make this
calculation.
Results
Serum chemical values. As shown in Table 3, serum urea
nitrogen and creatinine fell significantly within 4 to 6 weeks
after initiating therapy with the analogue supplement. Serum
albumin and transferrin rose significantly. Serum calcium
scarcely changed, but phosphate fell from a mean of 4.9 mg/dl
to 3.9 mg/dl. Although this latter change is not significant
statistically, it is worthy of note that the three patients who had
hyperphosphatemia before treatment (patients 1, 3 and 4;
average initial phosphate 6.9 mg/dl) became normophosphatem-
ic (average phosphate at 4 to 6 weeks, 3.7 mg/dl). Furthermore,
none of the other patients developed hyperphosphatemia or
hypophosphatemia. Other serum chemical values, including
sodium, potassium, chloride, carbon dioxide, glucose, triglyc-
erides, cholesterol, and uric acid did not change. Alkaline
phosphatase increased slightly but insignificantly at 4 to 6
weeks. No further statistically significant changes in any of
these values were found in the ensuing months.
Nitrogen balance. As shown in Table 4, nitrogen intake with
this regimen was, on the average 1.36 g lower than with the
control diet. Urea nitrogen appearance, calculated as the sum of
urine urea nitrogen and the rate of change of the body urea
nitrogen pool, fell from an average of 4.5 g/day to 3.4 g/day with
the analogue mixture (P < 0.01). No change occurred in the
other components of nitrogen excretion. Thus, the nitrogen
contained in feces and urinary nonurea nitrogen ranged from
1.63 to 3.11 gN/day, similar to values we have previously found
in patients with chronic renal failure [12, 21, 23, 24].
Nitrogen balance was on the average minimally, but insignifi-
cantly, positive in the control period. Because the amount of
protein in the control diet was chosen from the dietary record of
each patient and because there was little or no indication of
protein malnutrition before therapy (Table 3), it is not surprising
that nitrogen balance was neutral. When the diet was changed
and the analogues were given, nitrogen balance remained
neutral; it improved significantly in only one patient (no. 3). If a
correction of 0.5 g/day is applied for unmeasured nitrogen
losses, balance becomes minimally, but insignificantly, nega-
tive during both periods.
The nitrogen balance data indicate that the analogues substi-
tuted for dietary essential amino acids, since nitrogen balance
becomes negative within 1 to 3 days when a single essential
amino acid is omitted from the diet [25]. We have made similar
observations in uremic subjects eating virtually protein-free
diets [21, 24]. Moreover, the analogue regimen was as effective
as the higher protein diet in maintaining long-term protein
nutrition since serum concentrations of albumin and transferrin
improved slightly (and remained within the normal range)
during long-term therapy (Table 3).
Plasma amino acids. Compared to normal subjects [261,
these patients exhibited significantly elevated plasma levels of
taurine, citrulline, cystine, and 3-methylhistidine, and signifi-
cantly decreased levels of threonine, serine, valine, isoleucine,
leucine, and tyrosine before beginning treatment. These
changes are similar to those reported in other series of patients
with CRF [1].
During treatment with the supplement, few statistically sig-
nificant changes in plasma amino acids were observed. Threo-
nine rose significantly during the first, second and third months
(+38 10 p.M, +89 18 p.M and +69 13 p.M, respectively).
Because mean initial threonine was only 32 p.M less than the
mean of normal controls, these results suggest that the threo-
nine content of the supplement may have been slightly too high.
Alloisoleucine rose by an average of 42 p.M. This change occurs
regularly in patients given racemic ketoisoleucine [27]. Tyro-.
sine, a component of the supplement, rose from 45 3 p.M
(normal = 74 4 p.M) to 72 9.5 p.M at the second month,
becoming normal. Lysine, which was normal initially (202 13
rose slightly (+33 10 p.M) at the second month, again
suggesting that a slightly lower dose might have sufficed. 3-
Methylhistidine, which was 46 3 p.M initially (normal = 5 I
p.M) fell by 9 2 p. after two months. This probably reflects a
reduced intake of meat. No other plasma amino acid concentra-
tion changed significantly, including those of the branched-
chain amino acids, ornithine or histidine.
Progression ofrenal insufficiency. Despite the fact that the
serum creatinine concentration fell by a small, but significant,
amount at 4 to 6 weeks, a change in the rate of progression of
renal insufficiency could be demonstrated in only one patient
(no. 1). The rate of change of reciprocal serum creatinine
concentration in this patient during treatment with "EE" was
Urea nitrogen, mgldl
Creatinine, mg/dl
Albumin, gidi
Transferrin, mg/dl
Calcium, mg/dl
Phosphorus, mgldl
a P value from paired comparison.
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Table 4. Components of nitrogen balance in patients treated with supplement "EE'
Mean 6.89 5.53' 4.32 4.29 1.11 0.99 1.05 0.86
5CM ±0.12 ±0.06 ±0.33 ±0.38 ±0.2! ±0.16 ±0.05 ÷0.07
0.42 0.62a 0.18 _0.94e +0.23 +0.32
±0.35 ±0.30 ±0.22 ±0.19 ±0.24 ±0.30
a Values are mean ± SEM.
b Components of nitrogen balance are: 'N' nitrogen intake; UUN, urinary urea nitrogen; NUUN, nonurea urinary nitrogen; FN, fecal nitrogen; I—
0, intake minus output nitrogen; , rate of change in urea nitrogen pool; bN, nitrogen balance.
KA represents the results while receiving analogue-based supplement.
d Significantly different from zero, P < 0.05.
Significantly lower than control by paired comparison in patients ito 6, P < 0.01.
slower (P < 0.02) compared to the rate before therapy. In six
others, no change occurred, and in two others, historical data
before therapy were insufficient for this type of analysis.
Discussion
All the patients in this study were rapidly approaching the
time when dialysis would become necessary. The data present-
ed indicate that this analogue-supplement regimen can forestall
the need for dialysis by an average of about 7 months, while
maintaining protein nutrition. In fact, nutrition improved, as
evidenced by significant increases in serum albumin and trans-
ferrin, correction of hyperphosphatemia, and improvement in
the plasma amino acid concentration pattern. It should be
added also that both the diet and the supplement were well
tolerated and readily accepted. To assess compliance, changes
in plasma alloisoleucine concentration were calculated because
this amino acid is present in trace amounts in the plasma of
normal subjects and patients with chronic renal failure, but
invariably is found in subjects receiving R,S-a-keto-3-methyl-
valerate, the ketoanalogue of isoleucine [271. In the present
study no patient had a plasma alloisoleucine level greater than 9
JM before beginning therapy. However, throughout the period
of study, alloisoleucine levels were increased in every sample
taken and were within the range we have previously found to
occur in hospitalized patients receiving this keto-analogue [11.
Others [141 have noted that 20 to 25 g mixed quality protein
diets supplemented with a source of essential amino acids are
more acceptable to renal failure patients than diets containing
40 g of predominantly high quality protein such as eggs and
cottage cheese.
The use of mixed salts formed between basic amino acids and
ketoanalogues has several advantages, compared to the calcium
salts of keto-analogues that have been studied previously [131.
These mixed salts are more soluble and palatable than the
calcium salts and also more soluble than the corresponding
branched-chain amino acids themselves [191. While calcium
supplementation has often been advocated in CRF [I], dangers
are attendant on its use especially in the presence of hyperphos-
phatemia [281. In three studies in which calcium salts of
ketoacids were employed, a few patients were reported to
develop hypercalcemia [16—181, but this has not been reported
in other studies [131. The extra calcium may also play a role in
the gastric distress reported in some patients receiving calcium
salts of ketoacids [1]; gastric distress was not a significant
complaint of the patients in the present study.
It remains to be determined whether or not this supplement
can slow the progression of renal insufficiency if started at a
somewhat earlier stage. Barsotti et a! [291 have observed a
marked reduction in the rate of decline of creatinine clearance
in a group of patients with CRF of moderate severity given
ketoacids as calcium salts.
In a recent compilation of the results of the plasma concentra-
tions of amino acids in chronic uremic patients, it was pointed
out that the concentrations of valine, isoleucine, and leucine are
subnormal in almost all reports [1]. In the intracellular water of
muscle in uremic adults, the concentration of isoleucine is
normal in the absence of severe protein restriction while leucine
is somewhat reduced and valine more so [30, 311. Treatment of
chronically uremic adults with a low protein diet and a supple-
ment of essential amino acids containing more leucine than
valine and more valine than isoleucine results in a normal or
nearly normal plasma level of isoleucine and valine; leucine
remains subnormal. This regimen also results in normal levels
of branched-chain amino acids in the intracellular water of
INb
Patient Control KAC
no. gNlday
UUNb
Control KA
gN/day
NUUNh
Control KA
gN/day
0.64 0.46
FN'
Control KA
gNlda),
1.00 0.94
I_Oh
Control KA
gVIday
+0.82 —0.16
÷0.14 ±0.31
b
Control KA
gNIday
+0.16 —0.37
±0.06
bN"
Control KA
gN/day
+0.66+0 2  17.05 5.41 4.60 4.17
2 6.82 5.46 4.13 3.99 1.95 1.53 1.16 0.96 —0.42 —1.02
±0.49 ±0.32
+0.04
±0.33
3 6.73 5.65 4.74 3.81 1.09 0.79 1.10 0.72 0.20 +0.32
±0.15 ±0.29
0.49
±0.32
4 6.72 5.28 3.69 3.63 0.53 0.59 1.10 1,15 +1.40 —0.09
±0.40 ±0.19
+0.32
±0.20
5 7.44 5.74 5.52 5.73 1.22 1.10 1.10 0.60 —0.40 —1.70037 ±0.21 0.08±0.21
6 6.61 5.51 3.26 3.09 1.21 1.54 0.84 1.01 +1.30 —0.13
±0.37 ±0.26
+1.15
±0.45
7 5.71 5.66 0.92 0.70 —1.58
±0.12
±0.15 ±0.15 ±0.34
—0.38 —0.46 —0.64
÷0.24 ±0.59 ±0.40
—1.37 +0.29 +1.69d
±0.13 ±0.35 ±0.32
—0.77 +1.08 +0.68
±0.14 ÷0.45 ±0.24
—1.75 —0.32 +0.05
±0.34 ±0.42 ±0.40
—0.87 +0.15 +0.74
±0.13 ÷0.58 ±0.29
—1.13 —0.45
±0.22 ±0.26
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muscle [301. Recently, a supplement containing 40 to 43% less
leucine and isoleucine and 18% more valine was given to
chronically uremic adults and its effect on plasma and intracel-
lular amino acid concentrations tested [2]. This supplement
contained twice as much valine as isoleucine, and isoleucine
and leucine were within the normal range as were the intracellu-
lar concentrations of all three branched-chain amino acids.
Rat-feeding experiments have shown that higher intakes of
leucine impair utilization of valine and isoleucine while high
intakes of the latter two amino acids do not impair utilization of
leucine except when leucine intake is very low [321. Thus, if
plasma amino acid levels are considered as the criterion of
nutritional adequacy of a given supplement, more valine and
less leucine and isoleucine should be given. On the other hand,
no difference in clinical efficacy was demonstrated between
various amino acid supplements despite varying effects on
plasma and intracellular amino acid concentrations [2, 301.
It is possible that the failure of plasma branched-chain amino
acid concentrations to rise with the present supplement is due
to the higher proportion of the keto-analogue of leucine. Admin-
istration of this analogue [20, 33] or leucine itself [34—371 results
in a decrease in the plasma concentration of isoleucine and
valine. However, this analogue has been shown to exert a
nitrogen-sparing effect during short-term starvation, an effect
not induced by leucine [20]. This may be a factor in the
improvement in protein nutrition observed in these patients
even though their plasma levels of branched-chain amino acids
remained low.
A unique feature of the supplement used in the present study
is the absence of tryptophan and phenylalanine in any form; in
addition, the proportion of the methionine analogue was very
low (about 1% of the total). Nevertheless, the concentrations of
phenylalanine and methionine in plasma did not fall. Trypto-
phan was not measured in this study, but was found not to
change in patients given a similar supplement devoid of trypto-
phan [19]. Nitrogen balance remained essentially neutral de-
spite the "unbalanced" supply of essential amino acids (Table
2) and a diet containing less protein than normal requirements.
Moreover, the sustained improvement in serum albumin and
transferrin suggests that protein nutrition was maintained dur-
ing the 63 months of therapy.
Inclusion of ornithine in the supplement may be useful for
two reasons. Intracellular ornithine concentration in muscle is
subnormal in chronic uremic patients on moderate protein
restriction [31]. Secondly, two recent reports [38, 39] have
documented mild hyperammonemia in chronic uremia, and
ornithine should tend to lower blood ammonia [261.
A comparative study of an analogue-based supplement with
an amino acid supplement, both containing tyrosine, arginine or
ornithine, and increased quantities of branched-chain com-
pounds (especially valine), would be of interest. To design the
supplements to be compared, measurements of the extent of
decarboxylation of the branched-chain ketoacids (as compared
with the corresponding amino acids) would be helpful. A
technique for making such measurements has been described
recently [40]. Two other studies in which analogue-based
supplements were compared with amino acid supplements,
when added to 20 to 25 g protein diets [17, 41] have shown the
analogues to be more efficacious. A third study [42] in which
nitrogen intake was substantially higher, reported no difference
in efficacy. Thus, nitrogen intake may be a critical factor in the
design of such studies.
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